RESUMO
BACKGROUND AND OBJECTIVE: Unintended duplicate prescriptions of anticoagulants increase the risk of serious adverse events. Clinical Decision Support Systems (CDSSs) can help prevent such medication errors; however, sophisticated algorithms are needed to avoid alert fatigue. This article describes the steps taken in our hospital to develop a CDSS to prevent anticoagulant duplication (AD). METHODS: The project was composed of three phases. In phase I, the status quo was established. In phase II, a clinical pharmacist developed an algorithm to detect ADs using daily data exports. In phase III, the algorithm was integrated into the hospital's electronic health record system. Alerts were reviewed by clinical pharmacists before being sent to the prescribing physician. We conducted a retrospective analysis of all three phases to assess the impact of the interventions on the occurrence and duration of ADs. Phase III was analyzed in more detail regarding the acceptance rate, sensitivity, and specificity of the alerts. RESULTS: We identified 91 ADs in 1581 patients receiving two or more anticoagulants during phase I, 70 ADs in 1692 patients in phase II, and 57 ADs in 1575 patients in phase III. Mean durations of ADs were 1.8, 1.4, and 1.1 calendar days during phases I, II, and III, respectively. In comparison to the baseline in phase I, the relative risk reduction of AD in patients treated with at least two different anticoagulants during phase III was 42% (RR: 0.58, CI: 0.42-0.81). A total of 429 alerts were generated during phase III, many of which were self-limiting, and 186 alerts were sent to the respective prescribing physician. The acceptance rate was high at 97%. We calculated a sensitivity of 87.4% and a specificity of 87.9%. CONCLUSION: The stepwise development of a CDSS for the detection of AD markedly reduced the frequency and duration of medication errors in our hospital, thereby improving patient safety.
Assuntos
Anticoagulantes , Sistemas de Apoio a Decisões Clínicas , Erros de Medicação , Humanos , Anticoagulantes/uso terapêutico , Erros de Medicação/prevenção & controle , Algoritmos , Sistemas de Registro de Ordens Médicas , Estudos Retrospectivos , Registros Eletrônicos de SaúdeRESUMO
Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by ≥20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the European Competence Network on Mastocytosis registry. Thirty-one (34%) patients had a diagnosis of MCL with an associated hematologic neoplasm (MCL-AHN). Chronic MCL (lack of C-findings) comprised 14% of patients, and only 4.5% had "leukemic MCL" (≥10% circulating MCs). KIT D816V was found in 62/85 (73%) evaluable patients; 9 (11%) individuals exhibited alternative KIT mutations, and no KIT variants were detected in 14 (17%) subjects. Ten evaluable patients (17%) had an abnormal karyotype and the poor-risk SRSF2, ASXL1, and RUNX1 (S/A/R) mutations were identified in 16/36 (44%) patients who underwent next-generation sequencing. Midostaurin was the most common therapy administered to 65% of patients and 45% as first-line therapy. The median overall survival (OS) was 1.6 years. In multivariate analysis (S/A/R mutations excluded owing to low event rates), a diagnosis of MCL-AHN (hazard ratio [HR], 4.7; 95% confidence interval [CI], 1.7-13.0; P = .001) and abnormal karyotype (HR, 5.6; 95% CI, 1.4-13.3; P = .02) were associated with inferior OS; KIT D816V positivity (HR, 0.33; 95% CI, 0.11-0.98; P = .04) and midostaurin treatment (HR, 0.32; 95% CI, 0.08-0.72; P = .008) were associated with superior OS. These data provide the most comprehensive snapshot of the clinicopathologic, molecular, and treatment landscape of MCL to date, and should help further inform subtyping and prognostication of MCL.
Assuntos
Leucemia de Mastócitos , Mastocitose Sistêmica , Mastocitose , Humanos , Leucemia de Mastócitos/diagnóstico , Leucemia de Mastócitos/genética , Mastocitose Sistêmica/diagnóstico , Mastocitose Sistêmica/tratamento farmacológico , Mastocitose Sistêmica/genética , Mastócitos , Cariótipo AnormalAssuntos
Anticoagulantes/uso terapêutico , Receptores Fc/uso terapêutico , Proteínas Recombinantes de Fusão/uso terapêutico , Trombocitopenia/tratamento farmacológico , Trombocitopenia/imunologia , Trombopoetina/uso terapêutico , Idoso de 80 Anos ou mais , Humanos , Masculino , Contagem de Plaquetas , Receptores de Trombopoetina/agonistas , Resultado do TratamentoRESUMO
In this report, an AML patient with an additional ring chromosome 8 was investigated in detail. Fluorescence in situ hybridization showed high amplification of MYC on the additional ring chromosome and signals on both chromosome 8 homologues. In addition to the amplified segment from 8q24, no additional chromosomal aberration was found by array comparative genomic hybridization. Real-time reverse-transcription polymerase chain reaction analysis revealed that MYC and TRIB1 (a gene also localized on 8q24, close to MYC) were clearly overexpressed when compared with healthy donors, acute myeloid leukemia patients without MYC amplification, chronic myeloid leukemia patients, and acute lymphatic leukemia patients. These results may indicate a key role of TRIB1 (and MYC) overexpression in the pathogenesis of a certain AML subtype.
Assuntos
Cromossomos Humanos Par 8 , Amplificação de Genes , Genes myc , Peptídeos e Proteínas de Sinalização Intracelular/genética , Leucemia Mieloide Aguda/genética , Proteínas Serina-Treonina Quinases/genética , Cromossomos em Anel , Feminino , Humanos , Hibridização in Situ Fluorescente , Pessoa de Meia-IdadeRESUMO
Sporopachydermia cereana is a rare yeast found in necrotic cactus tissue, predominantly in the Americas. Infection in humans with clinical data has only been reported in four patients so far, all of whom died, either directly from the pathogen or from other complications of immunosuppression. Treatment of the yeast is complicated by difficulties in identification of the pathogen with conventional diagnostic techniques and by intrinsic resistance to echinocandins. The first patient to survive a disseminated infection with S. cereana is presented herein. The patient had acute myeloid leukemia and was treated successfully with antifungal therapy and subsequently underwent a successful allogeneic hematopoietic stem cell transplantation.
Assuntos
Fungemia/diagnóstico , Leucemia Mieloide Aguda/complicações , Linfonodos/patologia , Saccharomycetales , Antifúngicos/uso terapêutico , Feminino , Fungemia/complicações , Fungemia/tratamento farmacológico , Fungemia/patologia , Transplante de Células-Tronco Hematopoéticas , Humanos , Terapia de Imunossupressão/efeitos adversos , Leucemia Mieloide Aguda/cirurgia , Linfonodos/microbiologia , Pessoa de Meia-Idade , NecroseRESUMO
We measured anti-Xa activity before and at 2, 4, 9 and 12 h after subcutaneous injection of 0.3 ml nadroparin (2850 IU anti-Xa) in normal-weight volunteers (median bodyweight 71 kg, n=5) and compared them to the anti-Xa activity after subcutaneous injection of 0.6 ml nadroparin (5700 IU anti-Xa) in obese patients (median bodyweight 134 kg, n=8). The resulting median anti-Xa activity after 4 h was 1.4 times greater in the group of obese patients. This finding suggests that a linear, weight-adjusted increase in the prophylactic dose of nadroparin does not result in a linear increase of anti-Xa activity in obese patients.
Assuntos
Anticoagulantes/administração & dosagem , Fator Xa/efeitos dos fármacos , Nadroparina/administração & dosagem , Obesidade , Trombose Venosa/prevenção & controle , Anticoagulantes/farmacologia , Área Sob a Curva , Peso Corporal , Compostos Cromogênicos , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos , Fator Xa/análise , Humanos , Cinética , Nadroparina/farmacologiaAssuntos
Anticoagulantes/uso terapêutico , Antitrombinas/uso terapêutico , Neoplasias/sangue , Neoplasias/complicações , Células Neoplásicas Circulantes/efeitos dos fármacos , Embolia Pulmonar/sangue , Embolia Pulmonar/tratamento farmacológico , Trombose Venosa/tratamento farmacológico , Administração Oral , Anticoagulantes/efeitos adversos , Antitrombinas/efeitos adversos , Interações Medicamentosas , Inibidores do Fator Xa/efeitos adversos , Inibidores do Fator Xa/uso terapêutico , Heparina de Baixo Peso Molecular/efeitos adversos , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Estudos Prospectivos , Resultado do Tratamento , Trombose Venosa/sangue , Vitamina K/antagonistas & inibidoresAssuntos
Anticoagulantes/efeitos adversos , Toxidermias/etiologia , Hipersensibilidade Tardia/induzido quimicamente , Nadroparina/efeitos adversos , Policitemia Vera/tratamento farmacológico , Polissacarídeos/uso terapêutico , Tromboembolia/prevenção & controle , Idoso , Anticoagulantes/administração & dosagem , Fondaparinux , Humanos , Injeções Subcutâneas , Masculino , Nadroparina/administração & dosagem , Policitemia Vera/complicações , Tromboembolia/etiologia , Resultado do TratamentoRESUMO
PURPOSE: We report the long-term results of a randomized clinical trial comparing induction therapy with once per week for 4 weeks single-agent rituximab alone versus induction followed by 4 cycles of maintenance therapy every 2 months in patients with follicular lymphoma. PATIENTS AND METHODS: Patients (prior chemotherapy 138; chemotherapy-naive 64) received single-agent rituximab and if nonprogressive, were randomly assigned to no further treatment (observation) or four additional doses of rituximab given at 2-month intervals (prolonged exposure). RESULTS: At a median follow-up of 9.5 years and with all living patients having been observed for at least 5 years, the median event-free survival (EFS) was 13 months for the observation and 24 months for the prolonged exposure arm (P < .001). In the observation arm, patients without events at 8 years were 5%, while in the prolonged exposure arm they were 27%. Of previously untreated patients receiving prolonged treatment after responding to rituximab induction, at 8 years 45% were still without event. The only favorable prognostic factor for EFS in a multivariate Cox regression was the prolonged rituximab schedule (hazard ratio, 0.59; 95% CI, 0.39 to 0.88; P = .009), whereas being chemotherapy naive, presenting with stage lower than IV, and showing a VV phenotype at position 158 of the Fc-gamma RIIIA receptor were not of independent prognostic value. No long-term toxicity potentially due to rituximab was observed. CONCLUSION: An important proportion of patients experienced long-term remission after prolonged exposure to rituximab, particularly if they had no prior treatment and responded to rituximab induction.